Rentokil Shorts Tick Up, but Bears Lack Conviction

Among the large environmental and facilities services names, RTO carries a relatively modest short position compared with more crowded peers in pest control. Short interest on the NYSE-listed ADR has climbed roughly 20% over the past month to around 3.3 million shares, though the float percentage data is not available for direct comparison. Days to cover remain low at 1.75, and borrowing costs are minimal at 0.40%, well below levels that would suggest meaningful bearish conviction.

The lending market reinforces that picture. Availability has tightened over the past week, dropping around 28% to 832% of short interest, but that still implies far more shares available to borrow than are currently lent out. The 52-week trough in availability was 67.5%, meaning the current setup is nowhere near a stressed borrow environment. Options positioning has edged up relative to recent norms: the put/call ratio moved to 0.11 on Monday, about 1.4 standard deviations above its 20-day average of 0.08, though the ratio remains near the low end of its 52-week range. That combination points to some pre-earnings hedging, but not the kind of defensive pile-on that would signal deep pessimism.

The debate around Rentokil going into Thursday's results centres on execution rather than direction. The company has posted strong EPS surprises infrequently, ranking in the 26th percentile on that measure, while analyst recommendation divergence sits in the 96th percentile, suggesting the Street is unusually split on the stock. Rentokil's PE ratio has expanded roughly 3 points over the past month to 16.5x, partly reflecting the stock's 21% one-month rally to $24.07. That move follows a sharp reversal of the July print, when the stock fell more than 20% in a single session on weak results. The recovery will be tested against whether Thursday's numbers justify a re-rating or merely extend a technical bounce.

The historical pattern sets a high bar in both directions. The July 2026 result produced a one-day drop of 20.6% and a five-day loss of nearly 17%. The October 2026 interim update, by contrast, generated an 8.2% single-day gain and a five-day move of 10.6%. That range of outcomes, from a double-digit rally to a double-digit collapse on consecutive events, reflects genuine uncertainty about whether Rentokil's North American integration is delivering the margin improvement the market has been waiting for. BlackRock disclosed a 12.7% stake as recently as October, adding over 83 million shares in the period, which is the most consequential ownership shift in the register and provides a backstop of institutional confidence at current levels.

The November 6 print is therefore less a referendum on whether Rentokil grows and more a test of whether North American margins are finally moving in the right direction after the disruption that defined the summer.